KOSDAQ - Delayed Quote KRW
MedPacto, Inc. (235980.KQ)
3,165.00
-20.00
(-0.63%)
At close: May 2 at 3:30:30 PM GMT+9
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Seong-Jin Kim | Founder & CEO | -- | -- | -- |
| Mr. Ki Baik Hahm M.D., Ph.D. | Executive Vice President of R&D | -- | -- | -- |
| Mr. Sunjin Hwang M.D. | Chief Medical Officer | -- | -- | -- |
| Dr. Timothy R. Allen | Executive Vice President of Clinical Development at MedPacto Therapeutics - U.S. | -- | -- | -- |
MedPacto, Inc.
Borim Building
92, Myeongdal-ro Seocho-gu
Seoul, 06668
South Korea
- Sector:
- Healthcare
- Industry: Biotechnology
Description
MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea.
Corporate Governance
MedPacto, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 14, 2025 at 10:59 AM UTC - May 19, 2025 at 12:00 PM UTC
MedPacto, Inc. Earnings Date
Recent Events
Recent Events Information Not Available